Format

Send to

Choose Destination
Cancer Causes Control. 2002 Aug;13(6):583-90.

Estrogen and estrogen-progestin replacement therapy and risk of postmenopausal breast cancer in Canada.

Author information

1
Department of Epidemiology and Public Health, Yale University School of Medicine, New Haven, CT, USA.

Abstract

OBJECTIVE:

To examine the association between hormone replacement therapy (HRT) use and breast cancer incidence and to determine whether the association differs according to type of regimen.

METHOD:

Data were collected in Ontario from 404 incident cases and 403 age frequency-matched controls, between 1995 and 1996, using a self-administered questionnaire.

RESULTS:

Multivariate analyses revealed an elevated odds ratio among long-term (> or = ten years) HRT users (odds ratio (OR) = 1.80, 95% confidence interval (CI) 1.06-3.06). Risk among long-term estrogen-progestin users was substantially higher (OR = 3.48, 95% CI 1.00-12.11) than risk among long-term users of estrogen alone (OR = 1.74, 95% CI 0.93-3.24). Among both estrogen and estrogen-progestin users, positive associations were not observed for durations of use less than ten years.

CONCLUSION:

These data suggest that long-term use of HRT increases the risk of breast cancer and that estrogen-progestin therapy may be more detrimental than estrogen use alone.

PMID:
12195648
[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center